Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Assembly Biosciences, Inc. (ASMB)

1.3   0 (0%) 12-06 10:23
Open: 1.29 Pre. Close: 1.3
High: 1.3 Low: 1.29
Volume: 4,931 Market Cap: 63(M)

Technical analysis

as of: 2022-12-06 10:16:19 AM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.76     One year: 1.98
Support: Support1: 1.2    Support2: 0.99
Resistance: Resistance1: 1.5    Resistance2: 1.7
Pivot: 1.33
Moving Average: MA(5): 1.3     MA(20): 1.34
MA(100): 1.77     MA(250): 1.85
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 20.8     %D(3): 23.6
RSI: RSI(14): 36.8
52-week: High: 2.45  Low: 1.2
Average Vol(K): 3-Month: 218 (K)  10-Days: 199 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ASMB ] has closed above bottom band by 21.1%. Bollinger Bands are 47.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.34 - 1.35 1.35 - 1.35
Low: 1.25 - 1.25 1.25 - 1.26
Close: 1.29 - 1.3 1.3 - 1.31

Company Description

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Headline News

Tue, 22 Nov 2022
Nintendo goes after SteamGridDB, likely for people doing emulation on Steam Deck - GamingOnLinux

Thu, 17 Nov 2022
IOTA to Release Smart Contract Network ‘Assembly’ And Distribute ASMB Token -

Wed, 09 Nov 2022
We're A Little Worried About Assembly Biosciences' (NASDAQ:ASMB) Cash Burn Rate - Simply Wall St

Wed, 09 Nov 2022
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB) - Nasdaq

Tue, 08 Nov 2022
Assembly Biosciences Earnings Miss, Revenue In line In Q3 By -

Tue, 08 Nov 2022
Assembly Biosciences: Q3 Earnings Snapshot - Houston Chronicle

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 49 (M)
Shares Float 45 (M)
% Held by Insiders 1.5 (%)
% Held by Institutions 34.5 (%)
Shares Short 1,410 (K)
Shares Short P.Month 1,400 (K)

Stock Financials

EPS -2.77
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.1
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -32.5
Return on Equity (ttm) -80.1
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.11
Sales Per Share 0
EBITDA (p.s.) -1.96
Qtrly Earnings Growth 0
Operating Cash Flow -85 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -0.47
PEG Ratio -0.1
Price to Book value 0.61
Price to Sales 0
Price to Cash Flow -0.75

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.